The fastest-growing consumer behavior shift isn’t driven by a trend, a digital platform, or a fickle generation: it’s a weight loss drug. GLP-1 adoption is accelerating so fast that Ozempic is outpacing iPhone adoption curves in the same timeframe. Retailers (both grocery and apparel) are treating this trend as a passing diet fad.
Join Shelley with Liza Amlani, Principal of Retail Strategy Group and Ali Furman, PwC’s Consumer Markets Industry Leader as they challenge retailers to confront how to serve customers when body sizes change faster than the systems built to serve them. One outlook? Up to 400 million apparel units could be misaligned with actual demand by 2027, with retailers facing up to a $5 billion margin hit from oversized inventory, returns, and markdowns.
Listen and learn why this s an opportunity, not a transaction, for retailers who build trust with consumers whose bodies, wardrobes, and identities are all in flux. That loyalty will outlast the drug itself.
Listen to the full episode by clicking here.
